Zacks Investment Research upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a sell rating to a hold rating in a research note released on Saturday morning.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other equities research analysts have also recently commented on the stock. Canaccord Genuity set a $35.00 price target on shares of Voyager Therapeutics and gave the stock a buy rating in a report on Tuesday, May 29th. HC Wainwright started coverage on shares of Voyager Therapeutics in a report on Monday, June 4th. They set a buy rating and a $30.00 price objective for the company. Wedbush raised shares of Voyager Therapeutics from a neutral rating to an outperform rating in a research report on Friday, May 11th. BidaskClub lowered shares of Voyager Therapeutics from a hold rating to a sell rating in a research report on Thursday, April 19th. Finally, BTIG Research reissued a buy rating on shares of Voyager Therapeutics in a research report on Sunday, May 13th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and an average target price of $30.50.
NASDAQ:VYGR traded down $0.22 during trading hours on Friday, reaching $18.16. The company had a trading volume of 280,078 shares, compared to its average volume of 434,751. Voyager Therapeutics has a twelve month low of $8.25 and a twelve month high of $31.91.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). The company had revenue of $2.58 million during the quarter, compared to analyst estimates of $3.00 million. Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%. research analysts anticipate that Voyager Therapeutics will post -3.12 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Voyager Therapeutics by 18.8% in the first quarter. BlackRock Inc. now owns 1,438,029 shares of the company’s stock worth $27,020,000 after acquiring an additional 227,266 shares during the period. BB Biotech AG raised its position in shares of Voyager Therapeutics by 29.4% in the first quarter. BB Biotech AG now owns 1,992,641 shares of the company’s stock valued at $37,442,000 after purchasing an additional 453,121 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in shares of Voyager Therapeutics in the first quarter valued at approximately $227,000. Teachers Advisors LLC raised its position in shares of Voyager Therapeutics by 42.0% in the fourth quarter. Teachers Advisors LLC now owns 32,814 shares of the company’s stock valued at $545,000 after purchasing an additional 9,699 shares during the period. Finally, Millennium Management LLC bought a new stake in shares of Voyager Therapeutics in the fourth quarter valued at approximately $4,579,000. 83.86% of the stock is currently owned by institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Further Reading: Understanding Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.